These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24459290)

  • 1. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation.
    Abdul-Rahim AH; Wong J; McAlpine C; Young C; Quinn TJ
    Heart; 2014 Apr; 100(7):557-62. PubMed ID: 24459290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
    Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
    Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry.
    Haeusler KG; Gerth A; Limbourg T; Tebbe U; Oeff M; Wegscheider K; Treszl A; Ravens U; Meinertz T; Kirchhof P; Breithardt G; Steinbeck G; Nabauer M;
    BMC Neurol; 2015 Aug; 15():129. PubMed ID: 26242880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study.
    Gussoni G; Di Pasquale G; Vescovo G; Gulizia M; Mathieu G; Scherillo M; Panuccio D; Lucci D; Nozzoli C; Fabbri G; Colombo F; Riva L; Baldo CI; Maggioni AP; Mazzone A;
    Eur J Intern Med; 2013 Jun; 24(4):324-32. PubMed ID: 23684591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prophylaxis in atrial fibrillation: searching for management improvement opportunities in the emergency department: the HERMES-AF study.
    Coll-Vinent B; Martín A; Malagón F; Suero C; Sánchez J; Varona M; Cancio M; Sánchez S; Montull E; Del Arco C; ;
    Ann Emerg Med; 2015 Jan; 65(1):1-12. PubMed ID: 25182543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis.
    Lee SJ; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B
    Int J Cardiol; 2015 Feb; 180():185-91. PubMed ID: 25463361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS(2) , CHA(2) DS(2) -VASc score, underuse of oral anticoagulation, and implications for preventive measures.
    Palm F; Kleemann T; Dos Santos M; Urbanek C; Buggle F; Safer A; Hennerici MG; Becher H; Zahn R; Grau AJ
    Eur J Neurol; 2013 Jan; 20(1):117-23. PubMed ID: 22788384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
    Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
    Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?
    Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.